eCancerMedicalScience, a leading open-access journal published by the eCancer Global Foundation, is dedicated to advancing the field of cancer research and oncology. With its inception in 2007, this esteemed journal has emerged as a pivotal platform for disseminating groundbreaking research, innovative treatments, and comprehensive reviews in the cancer domain. Based in the United Kingdom, eCancerMedicalScience has continuously contributed to the academic community with its rigorous peer-review process and broad-ranging scope, now encompassing topics from clinical oncology to molecular biology. Currently ranked in the Q3 quartile for both Cancer Research and Oncology in 2023, the journal provides a significant opportunity for researchers, professionals, and students to access valuable insights and share their findings within a global network. The commitment to open access ensures that knowledge is readily available, fostering collaborative efforts to combat cancer and improve patient outcomes.

Case Reports in Oncology is a peer-reviewed journal published by KARGER, dedicated to the dissemination of high-quality case studies and clinical reports in the field of oncology. Since its transition to Open Access in 2008, this Swiss-based journal has aimed to broaden the accessibility of key findings to a global audience of researchers, healthcare professionals, and students. The journal is positioned in the Q3 quartile for oncology, indicating its valuable contribution to the field, while also holding a Scopus rank of 294 out of 404 in Medicine, with a percentile of 27%. However, its open access model ensures that even those outside of traditional academic institutions can engage with critical advancements and novel insights from the oncology community. With a publication span extending from 2010 to 2024, Case Reports in Oncology serves as a crucial platform for sharing unique clinical experiences and innovative treatment strategies, ultimately enriching the practice and study of oncology.

Rare Tumors, published by SAGE Publications Ltd, is a premier open-access journal dedicated to advancing the understanding and research of rare neoplasms. With the ISSN 2036-3605 and E-ISSN 2036-3613, this journal provides a vital platform for sharing innovative research findings and clinical insights since its inception in 2009. Situated in Italy, Rare Tumors has a converged publication timeline from 2010 to 2024 and aims to foster a supportive community for researchers and professionals in the oncology and histology fields. It has achieved a notable Q3 ranking in Oncology and Q4 in Histology as of 2023, reflecting its crucial role in bridging the knowledge gap in these specialized areas. Despite its relatively humble Scopus ranks, the journal's open-access model ensures that vital information reaches a broad audience, including those in academia, clinical practice, and beyond. It aspires to not only document rare tumor cases but also stimulate dialogue on their diagnosis, treatment, and management strategies, making it an indispensable resource for anyone dedicated to tackling the challenges posed by rare tumors.

LUNG CANCER, published by Elsevier Ireland Ltd, is a pivotal academic journal dedicated to advancing knowledge in the fields of Cancer Research, Oncology, and Pulmonary and Respiratory Medicine. With an impressive impact factor reflected by its Q1 ranking across three key categories for 2023, this journal occupies a prestigious position within the research community, emphasizing quality and significance in published works. Since its inception in 1985, LUNG CANCER has provided a comprehensive platform for researchers and clinicians to disseminate findings and novel insights, enhancing the understanding and treatment of lung cancer. The journal stands out with Scopus rankings, placing it in the top percentile across multiple relevant fields, including a notable rank of #20 in Pulmonary and Respiratory Medicine. By fostering collaboration among scholars, the journal aims to facilitate innovative research and promote evidence-based practices that could transform patient outcomes. As such, LUNG CANCER is an essential resource for those navigating this complex area of study, from seasoned researchers to aspiring professionals.

The Japanese Journal of Clinical Oncology, published by Oxford University Press, is a pivotal platform for advancing knowledge in the fields of cancer research, oncology, and related medical disciplines. Since its inception in 1971, this journal has contributed significantly to the dissemination of cutting-edge research and clinical practices, featuring a breadth of scholarly articles that cater to the needs of researchers, practitioners, and students alike. With an impact factor reflecting its robust reputation, the journal is ranked in the Q3 category for both Cancer Research and Oncology, and Q2 in Medicine (miscellaneous), and Radiology, Nuclear Medicine and Imaging as of 2023. These rankings, alongside the journal's Scopus rankings, signify its important role in the scientific community and its commitment to fostering innovative research. Although it is not an Open Access journal, the Japanese Journal of Clinical Oncology continues to provide valuable insights and educational resources, making it essential for anyone engaged in the fight against cancer.

Cancer Management and Research, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to advancing the field of oncology. Since its inception in 2009, this journal has established itself as a vital resource for researchers, clinicians, and healthcare professionals focused on cancer treatment and management. With its robust impact factor and impressive Scopus ranking in the 77th percentile of oncology medicine, it provides a prominent platform for sharing high-quality research. The journal covers a wide range of topics within cancer management, including innovative therapeutic strategies, clinical trials, patient care, and health policy, ensuring a comprehensive approach to current challenges in the field. Operating from New Zealand, it invites contributions that can shape the future of oncology and improve patient outcomes globally, making it an essential addition to the libraries of those engaged in cancer research and practice.

The Lancet Oncology is a premier peer-reviewed journal published by Elsevier Science Inc., recognized as a leading authority in the field of oncology. With an ISSN of 1470-2045 and E-ISSN 1474-5488, this esteemed journal boasts an impressive 2023 impact factor placing it in the Q1 category of oncology—reflecting its role as a critical resource for cutting-edge research. The journal publishes high-quality articles covering novel scientific discoveries, clinical advancements, and public health issues related to cancer treatment and prevention. It is ranked #5 out of 404 in the Scopus Medicine _ Oncology category, demonstrating its influence and relevance in the field, with an outstanding rank in the 98th percentile. Operating from its base in the United Kingdom, The Lancet Oncology spans a comprehensive timeframe from 2000 to 2024, making it a vital repository of oncology literature. Although it does not primarily operate on an open-access model, its significant subscription base ensures that a wealth of knowledge is accessible to researchers, professionals, and students alike, fostering a profound understanding and advancement in oncology.

ESMO Open is a premier open-access journal published by Elsevier, dedicated to advancing research in the fields of cancer and oncology. Since its inception in 2016, the journal has established itself as a vital resource for researchers, clinicians, and healthcare professionals, providing a platform for disseminating high-quality, peer-reviewed research. With an impressive Q1 ranking in both Cancer Research and Oncology based on the 2023 category quartiles, ESMO Open ranks within the top tier of its field, showcasing its commitment to excellence and innovation. The journal’s inclusion in Scopus rankings further emphasizes its significant impact, with remarkable placements in the 88th and 83rd percentiles for Oncology and Cancer Research, respectively. Operating under an open access model, ESMO Open ensures that cutting-edge findings and insights are readily available to the global academic community, fostering collaboration and knowledge-sharing to further enhance the understanding and treatment of cancer.

International Journal of Clinical Oncology, published by SPRINGER JAPAN KK, is a leading peer-reviewed journal dedicated to advancing research and clinical practices in the fields of oncology, hematology, and surgery. With its impact factor reflecting its significance and reach in the academic community, this journal serves as a solid platform for researchers, professionals, and students to share and disseminate groundbreaking discoveries and methodologies. Notably, it has secured prestigious rankings in the Q1 category in Medicine (miscellaneous) and Surgery, and Q2 in Hematology and Oncology, illustrating its prominent position in the medical literature. The journal's comprehensive scope addresses pivotal clinical issues from 1996 through 2024, further solidifying its relevance in the ever-evolving landscape of cancer research. Despite not offering open access, the depth and quality of research articles ensure that vital information remains accessible to those committed to improving clinical outcomes in oncology. With a focus on innovative treatments and patient care, the International Journal of Clinical Oncology embodies a commitment to fostering excellence in medical research.

CHEMOTHERAPY, published by KARGER, is a premier academic journal established in 1960, dedicated to disseminating cutting-edge research and advancements in the fields of drug discovery, infectious diseases, oncology, and pharmacology. With an impressive Scopus ranking placing it in the Q2 category for major disciplines such as Drug Discovery and Infectious Diseases, this journal provides an invaluable platform for researchers and professionals aiming to explore new therapeutic approaches and methodologies. Located in the heart of Switzerland, its publications are a key resource for anyone looking to stay informed about the latest developments and trends in the pharmacological sciences. Researchers can benefit from its diverse scope while contributing to a growing body of knowledge that emphasizes the importance of effective chemotherapeutic strategies in modern medicine. Despite not being an Open Access journal, CHEMOTHERAPY remains committed to maintaining a rigorous peer-review process, ensuring the highest quality of published work.